Spero Therapeutics (FRA:2HA) EBIT : €-2.25 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics EBIT?

Spero Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €-16.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €-2.25 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Spero Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 was -129.57%. Spero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -2,083.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Spero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 9.11%.

Spero Therapeutics EBIT Historical Data

The historical data trend for Spero Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics EBIT Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-56.89

-64.35

-77.72

-41.36

23.30

Spero Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															3.16	45.07	-12.86	-17.71	-16.75

Competitive Comparison of Spero Therapeutics's EBIT

For the Biotechnology subindustry, Spero Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's EV-to-EBIT falls into.

Spero Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.25 Mil.

Spero Therapeutics (FRA:2HA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Spero Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-67.008 * ( 1 - 1.66% )	/	( (68.058	+	33.658)	/ 2 )
=	-65.8956672	/	50.858
=	-129.57 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	139.239	-	12.164	-	( 59.017	-	max(0, 42.393	-	113.541	+	59.017	))
=	68.058

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	121.78	-	19.385	-	( 68.737	-	max(0, 44.235	-	118.596	+	68.737	))
=	33.658

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Spero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-67.008	/	( ( (3.385 + max(-37.815, 0))	+	(3.046 + max(-40.816, 0)) )	/	2 )
=	-67.008	/	( ( 3.385	+	3.046 )	/	2 )
=	-67.008	/	3.2155
=	-2,083.91 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.969)	-	(12.164	+	28.62	+	0)
=	-37.815

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.852)	-	(19.385	+	23.284	+	-0.0010000000000048)
=	-40.816

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Spero Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-2.253	/	-24.726
	=	9.11 %

Spero Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines